Mankind Pharma Share Price & Stock Analysis

Mankind Pharma (NSE: MANKIND, BSE: 543904) is a New Delhi, Delhi-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,09,870 Cr, it ranks #108 by market cap among the 6,197 Indian listed companies on FinBizNet, and #6 of 86 in Medicinal Chemicals and Botanical Products. At ₹2,640.00 (as of 16 Nov 2026), the share price is 2.4% below its 52-week high of ₹2,705.00 and 38.2% above its 52-week low of ₹1,909.70. The share price is up 16.7% over one year and up 9.8% over three months.

Key Metrics

Current Price₹2,640.00
Market Cap₹1,09,870 Cr
NSE SymbolMANKIND
BSE Code543904
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E Ratio57
Return on Equity12.45%
Return on Assets6.31%
52-Week Range₹1,909.70 – ₹2,705.00
1-Year Price Change+16.7%
3-Month Price Change+9.8%
Beta (1Y)0.37
Dividend Yield0.08%
HeadquartersNew Delhi, Delhi
Websitewww.mankindpharma.com

Latest Quarterly Results — Q2 FY27

Revenue₹4,338 Cr
Net Profit₹716 Cr
Net Margin16.5%
EPS (Basic)₹17.23
Basisconsolidated

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Mankind Pharma Quarterly Revenue and Profit Trend

Mankind Pharma reported revenue of ₹4,338 Cr in Q2 FY27, up 17.3% from ₹3,697 Cr in Q2 FY26 and up 7.6% from ₹4,031 Cr in Q1 FY27. It posted a net profit of ₹716 Cr for the quarter, against a net profit of ₹520 Cr in Q2 FY26 (up 37.7%). Across the 6 quarters from Q1 FY26 to Q2 FY27, quarterly revenue ranged from ₹3,443 Cr (Q4 FY26) to ₹4,338 Cr (Q2 FY27). The company was profitable in each of these 6 quarters.

QuarterRevenueNet ProfitNet Margin
Q2 FY27₹4,338 Cr₹716 Cr16.5%
Q1 FY27₹4,031 Cr₹574 Cr14.2%
Q4 FY26₹3,443 Cr₹559 Cr16.2%
Q3 FY26₹3,567 Cr₹414 Cr11.6%
Q2 FY26₹3,697 Cr₹520 Cr14.1%
Q1 FY26₹3,570 Cr₹445 Cr12.5%

Consolidated figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 72.62% of Mankind Pharma's shares as of Sept 2026, against 72.67% in Sept 2025 (−0.05 percentage points). Delivery averaged 50.3% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Mankind Pharma

Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory diseases, etc. It also provides consumer healthcare products, such as condoms, pregnancy detection kits, oral contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations. In addition, the company engages in the trading and exporting of pharmaceutical and health care products; manufacture of packing materials, ayurvedic products, and consumer goods; real estate, leasing, and hospitality businesses; trading of agricultural products; and provision of IT services. It offers its products under the Manforce, Moxi Kind-Cv, AmLokind-At, Unwanted-Kit, Prega News, Dydroboo

Products and Services

1. Pharmaceuticals-This segment develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products. 2. 0-0 3. 0-0 4. 0-0

Mankind Pharma vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Glenmark Pharmaceuticals Limited₹75,556 Cr55.114.07%₹4,157 Cr+45.7%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Mankind Pharma?

Mankind Pharma is trading at ₹2,640.00, with a market capitalisation of ₹1,09,870 Cr.

Which sector does Mankind Pharma belong to?

Mankind Pharma operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Mankind Pharma?

Mankind Pharma has a P/E of 57 and a return on equity of 12.45%.

What is the stock symbol of Mankind Pharma?

Mankind Pharma is listed on the NSE under the symbol MANKIND and on the BSE under the scrip code 543904.

How has Mankind Pharma's share price moved over the past year?

Mankind Pharma's share price is up 16.7% over one year and up 9.8% over three months. Its 52-week range is ₹1,909.70 to ₹2,705.00.

What were Mankind Pharma's latest quarterly results?

In Q2 FY27, Mankind Pharma reported revenue of ₹4,338 Cr and net profit of ₹716 Cr, with basic EPS of ₹17.23 (consolidated, parsed from the company's exchange filing).

How have Mankind Pharma's revenue and profit changed over the past year?

Mankind Pharma reported revenue of ₹4,338 Cr in Q2 FY27, up 17.3% from ₹3,697 Cr in Q2 FY26 and up 7.6% from ₹4,031 Cr in Q1 FY27.

What is the promoter holding in Mankind Pharma?

Promoters held 72.62% of Mankind Pharma's shares as of Sept 2026, against 72.67% in Sept 2025 (−0.05 percentage points).

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.